ReP USP - Resultado da busca

Filtros : "HISTOLOGIA" "Mount Sinai School of Medicine, Department of Pharmacology and Systems Therapeutics, United States of America" Removidos: "EPIDEMIOLOGIA" "Costa, Fabiano Gonçalves" "ARTIGO DE PERIODICO-DIVULGACAO" Limpar

Filtros

Collaboration
Normalized affiliation
Non normalized affiliation
- mount sinai school of medicine, department of pharmacology and systems therapeutics, united states of america (2)
- albert einstein college of medicine, department of molecular pharmacology, united states of america (1)
- butantan institute, center for applied toxinology, brazil (1)
- butantan institute, laboratory of pathophysiology, brazil (1)
- mount sinai school of medicine, department of pharmacology and systems, united states of america (1)

Artigo de periodico
Novel endogenous peptide agonists of cannabinoid receptors (2009)
Gomes, Ivone; Grushko, Julia S.; Golebiewska, Urszula; Hoogendoorn, Sascha; Gupta, Achla; Heimann, Andrea S.; Ferro, Emer Suavinho ; Scarlata, Suzanne; Fricker, Lloyd D.; Devi, Lakshmi A.
Source: Faseb Journal. Unidade: ICB
Assunto: HISTOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GOMES, Ivone et al. Novel endogenous peptide agonists of cannabinoid receptors. Faseb Journal, v. 23, n. 9, p. 3021-3029, 2009Tradução . . Disponível em: https://doi.org/10.1096/fj.09-132142. Acesso em: 27 ago. 2024.
APA
Gomes, I., Grushko, J. S., Golebiewska, U., Hoogendoorn, S., Gupta, A., Heimann, A. S., et al. (2009). Novel endogenous peptide agonists of cannabinoid receptors. Faseb Journal, 23( 9), 3021-3029. doi:10.1096/fj.09-132142
NLM
Gomes I, Grushko JS, Golebiewska U, Hoogendoorn S, Gupta A, Heimann AS, Ferro ES, Scarlata S, Fricker LD, Devi LA. Novel endogenous peptide agonists of cannabinoid receptors [Internet]. Faseb Journal. 2009 ; 23( 9): 3021-3029.[citado 2024 ago. 27 ] Available from: https://doi.org/10.1096/fj.09-132142
Vancouver
Gomes I, Grushko JS, Golebiewska U, Hoogendoorn S, Gupta A, Heimann AS, Ferro ES, Scarlata S, Fricker LD, Devi LA. Novel endogenous peptide agonists of cannabinoid receptors [Internet]. Faseb Journal. 2009 ; 23( 9): 3021-3029.[citado 2024 ago. 27 ] Available from: https://doi.org/10.1096/fj.09-132142
Artigo de periodico
Hemopressin is an inverse agonist of 'CB IND. 1' cannabinoid receptors (2007)
Heimann, Andrea S.; Gomes, Ivone; Dale, Camila Squarzoni ; Pagano, Rosana L.; Grupta, Achla; Souza, Laura L. de; Luchessi, Augusto D.; Castro, Leandro M.; Giorgi, Renata; Rioli, Vanessa; Ferro, Emer Suavinho ; Devi, Lakshmi A.
Source: Proceedings of the National Academy of Sciences of the United States of America. Unidade: ICB
Assunto: HISTOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HEIMANN, Andrea S. et al. Hemopressin is an inverse agonist of 'CB IND. 1' cannabinoid receptors. Proceedings of the National Academy of Sciences of the United States of America, v. 104, n. 51, p. 20588-20593, 2007Tradução . . Acesso em: 27 ago. 2024.
APA
Heimann, A. S., Gomes, I., Dale, C. S., Pagano, R. L., Grupta, A., Souza, L. L. de, et al. (2007). Hemopressin is an inverse agonist of 'CB IND. 1' cannabinoid receptors. Proceedings of the National Academy of Sciences of the United States of America, 104( 51), 20588-20593.
NLM
Heimann AS, Gomes I, Dale CS, Pagano RL, Grupta A, Souza LL de, Luchessi AD, Castro LM, Giorgi R, Rioli V, Ferro ES, Devi LA. Hemopressin is an inverse agonist of 'CB IND. 1' cannabinoid receptors. Proceedings of the National Academy of Sciences of the United States of America. 2007 ; 104( 51): 20588-20593.[citado 2024 ago. 27 ]
Vancouver
Heimann AS, Gomes I, Dale CS, Pagano RL, Grupta A, Souza LL de, Luchessi AD, Castro LM, Giorgi R, Rioli V, Ferro ES, Devi LA. Hemopressin is an inverse agonist of 'CB IND. 1' cannabinoid receptors. Proceedings of the National Academy of Sciences of the United States of America. 2007 ; 104( 51): 20588-20593.[citado 2024 ago. 27 ]

Digital Library of Intellectual Production of Universidade de São Paulo 2012 - 2024